Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference scheduled for April 7-10, 2025. The company's management team will deliver a presentation on April 9, 2025, from 1:30 - 2:10 pm ET.
The presentation will feature key executives including CEO Ben Zeskind, CSO Brett Hall, CMO Igor Matushansky, CBO Harold Brakewood, CLO Michael Bookman, and CAO Mallory Morales. They will discuss Immuneering's pipeline, platform, and business strategy. The event will include both a company presentation and one-on-one investor meetings.
Interested parties can access the live webcast and archived recording through the Investor Relations section of Immuneering's website under Events & Presentations.
Immuneering (Nasdaq: IMRX), un'azienda oncologica in fase clinica, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute, prevista per il 7-10 aprile 2025. Il team di gestione dell'azienda presenterà il 9 aprile 2025, dalle 13:30 alle 14:10 ET.
La presentazione vedrà la partecipazione di importanti dirigenti, tra cui il CEO Ben Zeskind, il CSO Brett Hall, il CMO Igor Matushansky, il CBO Harold Brakewood, il CLO Michael Bookman e il CAO Mallory Morales. Discuteranno del pipeline, della piattaforma e della strategia aziendale di Immuneering. L'evento includerà sia una presentazione dell'azienda che incontri individuali con gli investitori.
Le parti interessate possono accedere alla diretta e alla registrazione archiviata tramite la sezione Relazioni con gli Investitori del sito web di Immuneering, sotto Eventi e Presentazioni.
Immuneering (Nasdaq: IMRX), una empresa de oncología en etapa clínica, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Atención Médica de Needham, programada para el 7-10 de abril de 2025. El equipo de gestión de la empresa realizará una presentación el 9 de abril de 2025, de 1:30 a 2:10 pm ET.
La presentación contará con la participación de ejecutivos clave, incluyendo al CEO Ben Zeskind, al CSO Brett Hall, al CMO Igor Matushansky, al CBO Harold Brakewood, al CLO Michael Bookman y a la CAO Mallory Morales. Discutirán sobre el pipeline, la plataforma y la estrategia comercial de Immuneering. El evento incluirá tanto una presentación de la empresa como reuniones individuales con inversores.
Las partes interesadas pueden acceder a la transmisión en vivo y a la grabación archivada a través de la sección de Relaciones con Inversores del sitio web de Immuneering, en Eventos y Presentaciones.
Immuneering (Nasdaq: IMRX), 임상 단계의 종양학 회사가 2025년 4월 7일부터 10일까지 예정된 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2025년 4월 9일 오후 1시 30분부터 2시 10분(ET)까지 발표를 진행할 예정입니다.
발표에는 CEO Ben Zeskind, CSO Brett Hall, CMO Igor Matushansky, CBO Harold Brakewood, CLO Michael Bookman, CAO Mallory Morales 등 주요 임원들이 참석할 것입니다. 그들은 Immuneering의 파이프라인, 플랫폼 및 비즈니스 전략에 대해 논의할 것입니다. 이 행사는 회사 발표와 1:1 투자자 미팅을 포함할 것입니다.
관심 있는 분들은 Immuneering 웹사이트의 투자자 관계 섹션에서 이벤트 및 프레젠테이션 아래에 있는 라이브 웹캐스트와 아카이브된 녹음을 이용할 수 있습니다.
Immuneering (Nasdaq: IMRX), une entreprise de cancérologie en phase clinique, a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Needham sur la Santé, prévue du 7 au 10 avril 2025. L'équipe de direction de l'entreprise fera une présentation le 9 avril 2025, de 13h30 à 14h10 ET.
La présentation mettra en vedette des cadres clés, y compris le PDG Ben Zeskind, le CSO Brett Hall, le CMO Igor Matushansky, le CBO Harold Brakewood, le CLO Michael Bookman et le CAO Mallory Morales. Ils discuteront du pipeline, de la plateforme et de la stratégie commerciale d'Immuneering. L'événement comprendra à la fois une présentation de l'entreprise et des réunions individuelles avec des investisseurs.
Les parties intéressées peuvent accéder à la diffusion en direct et à l'enregistrement archivé via la section Relations Investisseurs du site Web d'Immuneering, sous Événements et Présentations.
Immuneering (Nasdaq: IMRX), ein Unternehmen in der klinischen Phase der Onkologie, hat seine Teilnahme an der 24. jährlichen Needham virtuellen Gesundheitskonferenz bekannt gegeben, die vom 7. bis 10. April 2025 stattfinden wird. Das Management-Team des Unternehmens wird am 9. April 2025 von 13:30 bis 14:10 Uhr ET eine Präsentation halten.
Die Präsentation wird wichtige Führungskräfte umfassen, darunter CEO Ben Zeskind, CSO Brett Hall, CMO Igor Matushansky, CBO Harold Brakewood, CLO Michael Bookman und CAO Mallory Morales. Sie werden über Immuneerings Pipeline, Plattform und Geschäftsstrategie sprechen. Die Veranstaltung umfasst sowohl eine Unternehmenspräsentation als auch Einzelgespräche mit Investoren.
Interessierte Parteien können über den Bereich Investor Relations auf der Website von Immuneering auf den Live-Stream und die archivierte Aufzeichnung zugreifen, unter Veranstaltungen & Präsentationen.
- None.
- None.
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Igor Matushansky, Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer, Michael Bookman, Chief Legal Officer, Secretary and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Format: Company Presentation and 1x1 Investor Meetings
Date/Time: April 9 from 1:30 – 2:10 pm ET
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Jenna Urban
jurban@cglife.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When is Immuneering (IMRX) presenting at the Needham Healthcare Conference 2025?
Which executives from IMRX will participate in the Needham Healthcare Conference?
How can investors watch Immuneering's (IMRX) Needham Conference presentation?
What topics will IMRX cover during the Needham Healthcare Conference presentation?
